NCT01851707 - A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone | Biotech Hunter

Enrollment

322

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

February 28, 2015

Conditions

Rheumatoid Arthritis

Interventions

DRUG

IPI-145

2 blinded capsules will be administered twice a day (morning and night) for 12 weeks.

DRUG

Placebo

2 blinded capsules will be administered twice a day (morning and night) for 12 weeks.

Trial Locations (64)

Unknown

Pleven

Plovdiv

Rousse

Sofia

Stara Zagora

Targovishte

Varna

Medellín

Bogota

Bucaramanga

Frankfurt

Halle

Budapest

Kecskemét

Mezőkövesd

Nyíregyháza

Veszprém

Mexico City

León

Guadalajara

Madero

Morelia

Monterrey

San Luis Potosí City

Mérida

Mexico City

Otahuhu

Wellington

Grodzisk

Krakow

Bialystok

Elblag

Krakow

Lublin

Nadarzyn

Poznan

Skierniewice

Sosnowiec

Stalowa Wola

Starachowice

Wroclaw

Baia Mare

Brăila

Bucharest

Oradea

Timișoara

Petrozavodsk

Ryazan

Moscow

Orenburg

Saint Petersburg

Saratov

Vladimir

Yaroslavl

Belgrade

Novi Sad

Donetsk

Kharkiv

Kyiv

Lviv

Poltava

Ternopil

Zaporizhzhya

All Listed Sponsors

lead

SecuraBio

INDUSTRY